1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 136,00 | 146,00 | 12:50 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Belite Bio begins rolling NDA submission for Stargardt treatment | 1 | Investing.com | ||
| Di | Belite Bio startet schrittweises Zulassungsverfahren für Stargardt-Therapie | 1 | Investing.com Deutsch | ||
| Di | Belite Bio, Inc: Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease | 230 | GlobeNewswire (Europe) | Belite expects to complete the new drug application submission in the second quarter of 2026Rolling submission initiated under Breakthrough Therapy Designation SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| BELITE BIO Aktie jetzt für 0€ handeln | |||||
| Di | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 13.04. | H.C. Wainwright bekräftigt "Buy"-Rating für Belite Bio mit Kursziel 200 $ | 1 | Investing.com Deutsch | ||
| 07.04. | Benchmark bestätigt Rating für Belite Bio aufgrund solider Liquidität und Studienfortschritt | 2 | Investing.com Deutsch | ||
| 31.03. | Belite Bio reports FY results | 1 | Seeking Alpha | ||
| 31.03. | Belite Bio, Inc: Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website | 1 | GlobeNewswire (USA) | ||
| 31.03. | BELITE BIO, INC - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 31.03. | BELITE BIO, INC - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 09.03. | Belite Bio: Positive Phase-3-Studiendaten für Tinlarebant bei Morbus Stargardt | 1 | Investing.com Deutsch | ||
| 04.03. | Mizuho reiterates Belite Bio stock rating on NDA timeline update | 1 | Investing.com | ||
| 04.03. | H.C. Wainwright raises Belite Bio stock price target on NDA timeline | 2 | Investing.com | ||
| 03.03. | Cantor Fitzgerald raises Belite Bio stock price target on pricing outlook | 3 | Investing.com | ||
| 03.03. | Belite Bio targets Q2 2026 NDA submission and $200M-$250M commercialization spend for Stargardt therapy while cash reserves surge | 2 | Seeking Alpha | ||
| 02.03. | Belite Bio Non-GAAP EPS of -$0.19 beats by $0.38 | 2 | Seeking Alpha | ||
| 02.03. | Belite Bio, Inc: Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update | 395 | GlobeNewswire (Europe) | Following positive topline results from the pivotal, global Phase 3 DRAGON trial of tinlarebant in adolescents with Stargardt disease type 1 (STGD1), the Company is on track to submit a New Drug Application... ► Artikel lesen | |
| 27.02. | Exploring Belite Bio's Earnings Expectations | 1 | Benzinga.com | ||
| 30.01. | BELITE BIO, INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 28.01. | H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target | 2 | Investing.com |
1 2 3 Weiter >>
59 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,15 | 0,00 % | Mesoblast: Wenn aus Vision plötzlich Umsatz wird | ||
| VALNEVA | 2,419 | -7,39 % | Valneva im freien Fall: 7,0% Verlust und das könnte erst der Anfang sein - Verpassen Sie das nicht! | ||
| PALATIN TECHNOLOGIES | 22,430 | 0,00 % | Morning Market Movers: Super Micro Computer, Bimergen Energy, Palatin Technologies, Intellicheck See Big Swings | HONG KONG (dpa-AFX) - At 7:40 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| OCUGEN | 1,506 | 0,00 % | Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease | GARDian3 trial enrollment and dosing completed (N=63) in less than nine monthsTopline results expected in 2Q27 with BLA to follow by mid-2027OCU410ST represents a potential first-in-class, one-time... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,960 | -0,88 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights | Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent... ► Artikel lesen | |
| SANGAMO THERAPEUTICS | 0,227 | +1,97 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results | Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across... ► Artikel lesen | |
| VIKING THERAPEUTICS | 28,950 | +0,35 % | Better Long-Term Buy: Eli Lilly or Viking Therapeutics? | ||
| BAVARIAN NORDIC | 25,920 | +1,25 % | Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S | COPENHAGEN, Denmark, April 21, 2026 - Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2025 was adopted. The Board of Directors'... ► Artikel lesen | |
| EDITAS MEDICINE | 2,800 | -0,71 % | Editas Medicine, Inc.: Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference | CAMBRIDGE, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today... ► Artikel lesen | |
| KUROS BIOSCIENCES | 25,320 | +1,61 % | Kuros Biosciences AG: Annual General Meeting of Kuros Biosciences approves all resolutions | Annual General Meeting of Kuros Biosciences approves all resolutions
Schlieren (Zurich), Switzerland, April 15, 2026 - Kuros Biosciences ("Kuros" or the "Company") a leader in next generation bone... ► Artikel lesen | |
| ABIVAX | 97,10 | -0,66 % | EQS-News: ABIVAX: Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
20.04.2026 /... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,600 | -0,23 % | H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target | ||
| GERON | 1,301 | +1,36 % | Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| BASILEA | 60,00 | 0,00 % | Basilea Pharmaceutica International Ltd, Allschwil: Basilea-Aktionäre genehmigen an der Generalversammlung 2026 alle Anträge des Verwaltungsrats | Allschwil, 15. April 2026
Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patienten zu helfen, die an schweren... ► Artikel lesen | |
| XOMA ROYALTY | 33,400 | -1,18 % | XOMA Royalty Corporation: XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements | Portfolio receipts: • Achieved over $50 million of cash receipts, including $33.6 million in royalties and $16.9 million milestones, in full year 2025 • Total receipts increased 9% with royalties... ► Artikel lesen |
BELITE BIO INC ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 138,00 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BELITE BIO INC ADR finden Sie auf Wallstreet Online.